Limited Offer
Colorectal Cancer
Disease and Advanced Drug Delivery Strategies
- 1st Edition - November 19, 2023
- Editors: Bhupendra Prajapati, Anil K. Philip, Sankha Bhattacharya
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 8 7 0 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 6 2 4 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 8 7 1 - 3
Colorectal Cancer: Disease and Advanced Drug Delivery Strategies examines the combined impact of basic clinical and medical treatments as well as recent advances in the field… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteColorectal Cancer: Disease and Advanced Drug Delivery Strategies examines the combined impact of basic clinical and medical treatments as well as recent advances in the field of colorectal cancer. With a strong focus towards colorectal cancer diagnosis, disease drug delivery, and diagnosis, the book also examines the Tumor microenvironment-responsive and site-specific nanoparticles for cancer theragnostics. Sections provide the opportunity to understand and diagnose the disease, describes screening methods, and update on drugs, including nano- and immunotherapy. Content includes clinical trials in colorectal cancer research and disease models that help better direct researchers and clinicians on how to diagnose and treat colorectal cancer.
- Provides a wealth of information on the latest research and developments in the science and treatment of colorectal cancer
- Contains new and innovative ways to treat colorectal cancer
- Reflects on basic clinical and medical methods and recent advances in colorectal cancer science
- Gives specific details about how nanoparticles can be used to target cancer cells or cancer treatment
- Covers tumor microenvironment, their challenges, and opportunities in colorectal cancer research
Researchers and graduate students on cancer research and bioinformatics, oncologists, Nano drug delivery systems, Pharmaceutical, Nano-material Sciences and Medical, Nursing, and other health care professionals, Clinical researchers
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- List of contributors
- Preface
- Acknowledgments
- Chapter 1. Colorectal cancer: understanding of disease
- Abstract
- 1.1 Introduction
- 1.2 Understanding of disease: colorectal cancer
- 1.3 Diagnosis for colorectal cancer
- 1.4 Treatment for colorectal cancer
- 1.5 Recent advances in the therapeutic interventions of colorectal cancer
- 1.6 Conclusion
- Abbreviations
- References
- Chapter 2. Impact of the microbiome on colorectal cancer development
- Abstract
- 2.1 Introduction
- 2.2 Gut microbiome and colorectal cancer
- 2.3 Gut microbiota and its derived metabolites
- 2.4 Host microbiota interactions with genomes and epigenomes
- 2.5 Linking antibiotic-microbiome: risk and attribution of leaky gut to colorectal cancer
- 2.6 Intestinal stem cells and colorectal cancer
- 2.7 Prognostic or diagnostic microbiome-associated early diagnosis
- 2.8 Therapeutic impact of the gut microbiome on the efficacy of chemotherapy
- 2.9 Preventive dietary mediators and their protective potential in colorectal cancer
- 2.10 Concluding remarks and outlook
- Abbreviations
- References
- Chapter 3. Advanced microfluidic systems for the colorectal cancer diagnosis and its clinical application
- Abstract
- 3.1 Introduction
- 3.2 Tumor markers used for colorectal cancer detection
- 3.3 Conventional methods used for diagnosis of colorectal cancer
- 3.4 Microfluidic system
- 3.5 Microfluidic models for diagnosis of cancer
- 3.6 Conclusion
- References
- Chapter 4. Transarterial radioembolization and its impacts on colon cancer treatment and diagnosis
- Abstract
- 4.1 Introduction
- 4.2 Colorectal cancer risk assessment
- 4.3 Colorectal cancer diagnosis and staging procedures
- 4.4 Treatments
- 4.5 Transarterial radioembolization
- 4.6 Principle and concept of radioembolization
- 4.7 Types of radionuclides microspheres
- 4.8 Glass microspheres
- 4.9 Resin microspheres
- 4.10 Radioembolization with 90Y as primary therapy for liver MCRC (Metastatic Colorectal Cancer)
- 4.11 Radioembolization with 90Y in grouping with second- or third-line chemotherapy for hepatic MCRC
- 4.12 Treatment methodology
- 4.13 Conclusion and future outlook
- References
- Chapter 5. Current drug therapy for colorectal cancer
- Abstract
- 5.1 Introduction
- 5.2 Molecular targets of the colorectal cancer drugs
- 5.3 Targeted drug therapy in colorectal cancer
- 5.4 Multidrug therapy approaches
- 5.5 Chances of drug resistance with colorectal targeting drugs
- 5.6 Conclusion
- Acknowledgment
- Abbreviation
- References
- Chapter 6. Recent advancements in immunotherapy for colorectal cancer
- Abstract
- 6.1 Introduction
- 6.2 Immunotherapy for colorectal cancers
- 6.3 Immuno-checkpoints for colorectal cancer
- 6.4 Immune-modulators
- 6.5 Cell transfer therapies
- 6.6 Monoclonal antibodies and vaccines
- 6.7 Recent promising biomarkers for colorectal cancer
- 6.8 Nanoengineered cancer immunotherapy approaches
- 6.9 Conclusion and open question
- Funding
- List of abbreviation
- References
- Chapter 7. Novel targeting formulations in colorectal cancer
- Abstract
- 7.1 Introduction
- 7.2 Epidemiology of colorectal cancer
- 7.3 Pathogenesis of colorectal cancer
- 7.4 Synthetic antiinflammatory drugs for colorectal cancer
- 7.5 Cyclodextrin-based nanoparticles
- 7.6 Conclusions
- References
- Chapter 8. Polymeric nanoparticles in colorectal cancer
- Abstract
- 8.1 Introduction
- 8.2 Polymers for drug delivery
- 8.3 Mechanisms of drug delivery and release in polymeric drug-delivery systems
- 8.4 Polymer degradation mechanism
- 8.5 Mechanisms of drug delivery and release in polymeric drug delivery systems
- 8.6 Therapeutic use of polymeric nanoparticles in colon cancer
- 8.7 Drugs for colon cancer therapy
- 8.8 Monoclonal antibodies drugs
- 8.9 Colon cancer treatments using polymers
- 8.10 Polymeric nanocarriers sensitive to temperature and redox potential
- 8.11 Patents and clinical trials
- 8.12 Conclusion
- Acknowledgments
- Abbreviations
- References
- Chapter 9. Lipid nanoparticles in colorectal cancer
- Abstract
- 9.1 Introduction
- 9.2 Mechanisms of action
- 9.3 Current lipid-based nanoplatforms
- 9.4 Deliverable targets for colorectal cancer treatment
- 9.5 Preclinical and clinical studies
- 9.6 Clinical studies
- 9.7 Conclusions
- Acknowledgments
- Funding
- Author contributions
- Competing interests
- Availability statement
- References
- Chapter 10. Micro and nanoemulsions in colorectal cancer
- Abstract
- 10.1 Introduction
- 10.2 Microemulsion
- 10.3 Nanoemulsion
- 10.4 Formulation of microemulsion/nanoemulsion
- 10.5 Components of microemulsion/nanoemulsion
- 10.6 Overview of patent situation
- 10.7 Pharmacokinetics and pharmacodynamics of developed nanoemulsion/microemulsion for colorectal cancer
- 10.8 Regulatory aspects
- 10.9 Challenges and future prospects
- 10.10 Conclusion
- Abbreviations
- References
- Chapter 11. A unique compilation of whole-systems approaches to curtail colon cancer through herbal medicine
- Abstract
- 11.1 Introduction
- 11.2 Herbal medicine in colorectal cancer
- 11.3 Regulatory status of these medicines
- 11.4 Clinical trials
- 11.5 Conclusion
- References
- Chapter 12. Bacteriotherapy in colorectal cancer
- Abstract
- 12.1 Colorectal cancer
- 12.2 Bacteriotherapy in treatment of colorectal cancer
- 12.3 Conclusion
- List of abbreviations
- References
- Chapter 13. Biomarkers and theranostics in colorectal cancer
- Abstract
- 13.1 Introduction
- 13.2 Biomarkers and theranostics in early diagnosis of colorectal cancer
- 13.3 Targeted therapies for treating metastatic colorectal cancer: role of biomarkers and theranostics
- 13.4 Theranostic nanoagents for diagnosis and treatment of colorectal cancer
- 13.5 Diagnostic biomarkers in colorectal cancer
- 13.6 Theranostic and biomarkers in colorectal cancer: future perspectives
- 13.7 Conclusion
- References
- Chapter 14. Advance precision medicine to combat colorectal cancer
- Abstract
- 14.1 Introduction
- 14.2 Development of advance precision medicine
- 14.3 Advanced precision medicine
- 14.4 Treatment with advance precision medicine
- 14.5 Challenges and opportunities
- 14.6 Conclusion
- References
- Chapter 15. Recent updates of clinical trials for colorectal cancer
- Abstract
- 15.1 Introduction
- 15.2 Classification of colorectal cancer based on immune score
- 15.3 Causes and etiogenesis of colorectal cancer
- 15.4 Prevention of colorectal cancer
- 15.5 Molecular target of colorectal cancer
- 15.6 Combining immunotherapy with other treatments for patients with colorectal cancer
- 15.7 Targeted therapies for metastatic colorectal cancer
- 15.8 Food and Drug Administration-approved drugs in a clinical trial for colorectal cancer
- 15.9 Identification of categorical risk in screening
- 15.10 Therapeutic vaccine for colorectal cancer
- 15.11 Natural anticancer and combination agents for colorectal cancer
- 15.12 Advancement in clinical trials for the treatment of colorectal cancer
- 15.13 History and future challenges of clinical trials of colorectal cancer
- 15.14 Conclusion
- Abbreviations
- References
- Chapter 16. Disease models in colorectal cancer research
- Abstract
- 16.1 Introduction
- 16.2 Search strategy
- 16.3 In vitro colorectal cancer models
- 16.4 Animal models for colorectal cancer
- 16.5 Chemically-triggered colorectal cancer
- 16.6 Mutagen-induced germline mutation models
- 16.7 Genetically engineered models
- 16.8 Other animal models
- 16.9 Conclusion
- Funding
- Conflict of interests
- References
- Chapter 17. An outlook into liposomal drug delivery of chemotherapeutic agents to combat colorectal cancer
- Abstract
- 17.1 Introduction
- 17.2 Pros and cons of liposomes for colorectal chemotherapy
- 17.3 Liposomal approaches for colorectal chemotherapy
- 17.4 Triggering modalities of liposomal formulations
- 17.5 Future perspective
- 17.6 Conclusion
- Abbreviations
- References
- Chapter 18. Novel targeting strategies on signaling pathways of colorectal cancer
- Abstract
- 18.1 Introduction
- 18.2 Molecular pathways involved in colorectal cancer
- 18.3 Colorectal cancer-related signaling pathways
- 18.4 Novel targeting strategy for targeting signaling pathway responsible for colorectal cancer
- 18.5 Conclusion
- Abbreviations
- References
- Chapter 19. Decipher the role of cancer stem cells in colorectal cancer based on molecular pathology and its clinical significance
- Abstract
- 19.1 Introduction
- 19.2 Normal stem cells—elixir of life and cancer stem cells—the enemy within
- 19.3 Molecular pathology of cancer stem cells
- 19.4 Insight into the clinical implication of cancer stem cells
- 19.5 Targeted drug delivery system in targeting colorectal cancer stem cells
- 19.6 Future perspective and challenges ahead for cancer stem cell-based therapy
- 19.7 Conclusion
- References
- Index
- No. of pages: 618
- Language: English
- Edition: 1
- Published: November 19, 2023
- Imprint: Academic Press
- Paperback ISBN: 9780443138706
- eBook ISBN: 9780443286247
- eBook ISBN: 9780443138713
BP
Bhupendra Prajapati
Dr. Prajapati is a Professor in Department of Pharmaceutics, Shree S.K.Patel College of Pharmaceutical Education and Research, Ganpat University, Gujarat, India. He has more than 20 years of academic and research experience, has published more than 100 research and review papers in international and national Journals. Under his editorial two book under process and he authored 20 book chapters in the field of novel drug delivery. He published two Indian patent and three application under evaluation. He is a reviewer in three high impact journals and is on the editorial board of several scientific journals.
Affiliations and expertise
Professor, Dept. of Pharmaceutics and Pharmaceutical Technology, Shree S.K. Patel College of Pharmaceutical Education & Research, Faculty of Pharmacy, Ganpat UniversityAP
Anil K. Philip
Dr. Anil Philip is currently working as Associate Dean (Head), School of Pharmacy, University of Nizwa, Oman. Among other credentials, he served as a member of the Health and Social Sciences sectorial grant committee of The Research Council, Oman, and as Faculty Mentored Undergraduate Research Program general supervisor to promote undergraduate research at the University of Nizwa. His research objectives and achievements have been in controlling/modifying the release of small/large molecules targeted to GI space using phase-transited delivery systems. He has worked extensively in the field of controlled/ modified drug release systems. Currently, his research focuses on developing nano-drug delivery systems, which can be targeted to the various body organs. He has guided students in areas of targeted drug delivery, has more than 40 original research publications in international peer-reviewed journals, and two patents on drug delivery systems.
Affiliations and expertise
Associate Dean (Head), School of Pharmacy, University of Nizwa, OmanSB
Sankha Bhattacharya
Dr. Sankha Bhattacharya did his Post Doctorate from the Indian Institute of Technology (BHU), Varanasi, INDIA (August 2018-August 2019) in cancer nanomedicine and molecular pharmaceutics. He is currently serving as an Associate Professor in the Department of Pharmaceutics, School of Pharmacy & Technology Management Shirpur, SVKM'S NMIMS Deemed-to-be University, India with 9.3 years of Research and Teaching experiences. He has published more than 32 national and 18 international papers in high impact factor and peer-reviewed journals. He also published five book chapters on the global platform.
Affiliations and expertise
Associate Professor, Department of Pharmaceutics, School of Pharmacy and Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, India